Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

LRRCC1 Inhibitors

LRRCC1, or Leucine-Rich Repeat and Coiled-Coil Domain-Containing 1, is a protein that, as its name suggests, contains domains that are rich in leucine residues and characterized by a coiled-coil structure. The leucine-rich repeat (LRR) is a protein structural motif that typically forms an α/β horseshoe fold, which is involved in protein-protein interactions. LRR motifs are known for their role in the formation of complexes, often being involved in various signaling pathways and cellular processes due to their ability to facilitate specific molecular interactions.

The coiled-coil domain is a structural motif that mediates the oligomerization of proteins, which is the process by which proteins form complexes through dimerization or higher-order associations. This domain is characterized by heptad repeats of amino acids where the first and fourth positions are typically occupied by hydrophobic residues, often leucine, which drive the coiling of α-helices around each other. Coiled-coil domains are fundamental in the formation of the cytoskeleton and various motor proteins, as well as in transcription factors and vesicle transport.In the context of LRRCC1, the combination of LRR and coiled-coil domains suggests a multifunctional role. LRRCC1 could be implicated in cellular signaling, acting as a scaffold for the assembly of multiprotein complexes, and may play a role in the regulation of various pathways through its mediated interactions. Additionally, the coiled-coil region implies a potential role in the structural organization within the cell, possibly influencing cytoskeletal dynamics or intracellular trafficking.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

A potent inhibitor of phosphoinositide 3-kinases (PI3K), which may indirectly affect LRRCC1-related signaling pathways.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Another PI3K inhibitor, used to study the role of PI3K in various cellular processes that might intersect with LRRCC1 functions.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

This compound inhibits p38 MAP kinase, potentially affecting stress response pathways that could intersect with LRRCC1 functions.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor, affecting cellular growth and proliferation pathways, possibly impacting LRRCC1's indirect roles.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$186.00
$707.00
88
(1)

A ROCK inhibitor, which may alter cytoskeletal dynamics and potentially intersect with LRRCC1-related processes.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

An inhibitor of MEK, which may indirectly affect signaling pathways involving LRRCC1.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, which could modify cellular stress responses potentially linked to LRRCC1.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

A proteasome inhibitor, could indirectly affect protein degradation pathways related to LRRCC1.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

A tyrosine kinase inhibitor, potentially impacting signaling pathways that may intersect with LRRCC1 functions.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Another tyrosine kinase inhibitor, which could indirectly affect pathways related to LRRCC1.